0001178913-23-003362.txt : 20231023 0001178913-23-003362.hdr.sgml : 20231023 20231023064318 ACCESSION NUMBER: 0001178913-23-003362 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231018 FILED AS OF DATE: 20231023 DATE AS OF CHANGE: 20231023 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: aMoon Growth Fund Limited Partnership CENTRAL INDEX KEY: 0001744099 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36138 FILM NUMBER: 231338476 BUSINESS ADDRESS: STREET 1: 34 YERUSHALAYIM RD. CITY: RAANANA STATE: L3 ZIP: 4350110 BUSINESS PHONE: 972(73)3989560 MAIL ADDRESS: STREET 1: 34 YERUSHALAYIM RD. CITY: RAANANA STATE: L3 ZIP: 4350110 FORMER NAME: FORMER CONFORMED NAME: aMoon 2 Fund Limited Partnership DATE OF NAME CHANGE: 20180620 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Ayala Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001100397 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 841521955 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9 DEER PARK DRIVE STREET 2: SUITE K-1 CITY: MONMOUTH JUNCTION STATE: NJ ZIP: 08852 BUSINESS PHONE: 732 545 1590 MAIL ADDRESS: STREET 1: 9 DEER PARK DRIVE STREET 2: SUITE K-1 CITY: MONMOUTH JUNCTION STATE: NJ ZIP: 08852 FORMER COMPANY: FORMER CONFORMED NAME: Advaxis, Inc. DATE OF NAME CHANGE: 20050105 FORMER COMPANY: FORMER CONFORMED NAME: GREAT EXPECTATIONS & ASSOCIATES INC DATE OF NAME CHANGE: 19991203 4 1 ownership.xml X0508 4 2023-10-18 1 0001100397 Ayala Pharmaceuticals, Inc. ADXS 0001744099 aMoon Growth Fund Limited Partnership 34 YERUSHALAIM ROAD BEIT GAMLA, 6TH FLOOR RA-ANANA L3 4350110 ISRAEL 0 0 1 0 0 Common Stock 2023-10-18 4 J 0 0 0.00 D 560602 D This Form 4 is filed to report that the beneficial interest of the Reporting Person in Ayala Pharmaceuticals, Inc., (the "Registrant") was reduced below 10% due to dilution resulting from issuance of approximately 5,913,480 shares of the Common Stock of the Registrant on October 18, 2023 to the former holders of Biosight Ltd. ("Biosight") upon the consummation on October 18, 2023 of the transaction contemplated by the Agreement and Plan of Merger and Reorganization, dated July 26, 2023, by and among the Registrant, Advaxis Israel Ltd. and Biosight. The transaction is more fully described in the Registrant's Form 8-K filed with the Securities and Exchange Commission on October 20, 2023. The reported shares are held of record by aMoon Growth Fund Limited Partnership ("aMoon Growth Fund"). aMoon Growth Fund G.P. Limited Partnership ("aMoon Growth Fund G.P.") is the sole General Partner of aMoon Growth Fund and aMoon General Partner Ltd. ("aMoon General Partner") is the sole General Partner of aMoon Growth Fund G.P. Dr. Yair Schindel is the sole shareholder of aMoon General Partner. By virtue of such relationships, aMoon Growth Fund G.P., aMoon General Partner and Dr. Schindel may have been deemed to have shared voting and investment power with respect to the shares held of record by aMoon Growth Fund. Each of aMoon Growth Fund G.P., aMoon General Partner and Dr. Schindel disclaims beneficial ownership of the shares held by aMoon Growth Fund except to the extent of its or his pecuniary interest therein, if any. /s/ Yair Schindel, on behalf of himself and the sole shareholder of aMoon General Partner Ltd., the sole General Partner of aMoon Growth Fund G.P. Limited Partnership, the sole General Partner of aMoon Growth Fund, Limited Partnership 2023-10-23